{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:38:58Z","timestamp":1791567538758,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["614739"],"award-info":[{"award-number":["614739"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10928-021-09791-8","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T12:04:24Z","timestamp":1642075464000},"page":"293-310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma\u00a0mansoni and S.\u00a0haematobium and Lao adults infected with Opisthorchis\u00a0viverrini"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7988-8617","authenticated-orcid":false,"given":"Christine","family":"Falcoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Guzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kova\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Meister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somphou","family":"Sayasone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"9791_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0001-706X(03)00029-9","volume":"86","author":"MJ Van Der Werf","year":"2003","unstructured":"Van Der Werf MJ, De Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86:125\u2013139","journal-title":"Acta Trop"},{"key":"9791_CR2","unstructured":"WHO (2020) Schistosomiaisis fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schistosomiasis"},{"key":"9791_CR3","doi-asserted-by":"publisher","first-page":"e4093","DOI":"10.1136\/bmj.e4093","volume":"344","author":"T Furst","year":"2012","unstructured":"Furst T, Sayasone S, Odermatt P, Keiser J, Utzinger J (2012) Manifestation, diagnosis, and management of foodborne trematodiasis. BMJ 344:e4093","journal-title":"BMJ"},{"key":"9791_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.idc.2012.03.008","volume":"26","author":"T Furst","year":"2012","unstructured":"Furst T, Duthaler U, Sripa B, Utzinger J, Keiser J (2012b) Trematode infections: liver and lung flukes. Infect Dis Clin N Am 26:399\u2013419","journal-title":"Infect Dis Clin N Am"},{"key":"9791_CR5","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1473-3099(11)70294-8","volume":"12","author":"T Furst","year":"2012","unstructured":"Furst T, Keiser J, Utzinger J (2012c) Global burden of human food-borne trematodiasis: a systematic review and meta-analysis. Lancet Infect Dis 12:210\u2013221","journal-title":"Lancet Infect Dis"},{"key":"9791_CR6","doi-asserted-by":"publisher","first-page":"5466","DOI":"10.1128\/AAC.02741-14","volume":"58","author":"I Meister","year":"2014","unstructured":"Meister I, Ingram-Sieber K, Cowan N, Todd M, Robertson MN, Meli C, Patra M, Gasser G, Keiser J (2014) Activity of praziquantel enantiomers and main metabolites against Schistosoma mansoni. Antimicrob Agents Chemother 58:5466\u20135472","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9791_CR7","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1371\/journal.pntd.0000357","volume":"3","author":"T Meyer","year":"2009","unstructured":"Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C (2009) Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis 3(1):e357","journal-title":"PLoS Negl Trop Dis"},{"key":"9791_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0004946","volume":"10","author":"AL Bustinduy","year":"2016","unstructured":"Bustinduy AL, Friedman JF, Kjetland EF, Ezeamama AE, Kabatereine NB, Stothard JR, King CH (2016) Expanding praziquantel (PZQ) access beyond mass drug administration programs: paving a way forward for a pediatric PZQ formulation for schistosomiasis. PLoS Negl Trop Dis 10:1\u20137","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"9791_CR9","doi-asserted-by":"publisher","first-page":"e1917","DOI":"10.1371\/journal.pntd.0001917","volume":"6","author":"JT Coulibaly","year":"2012","unstructured":"Coulibaly JT, N\u2019Gbesso YK, Knopp S, Keiser J, N\u2019Goran EK, Utzinger J (2012) Efficacy and safety of praziquantel in preschool-aged children in an area co-endemic for Schistosoma mansoni and S. haematobium. PLoS Negl Trop Dis 6(12):e1917","journal-title":"PLoS Negl Trop Dis"},{"key":"9791_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1093\/jac\/dkt491","volume":"69","author":"P Olliaro","year":"2014","unstructured":"Olliaro P, Delgado-Romero P, Keiser J (2014) The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother 69:863\u2013870","journal-title":"J Antimicrob Chemother"},{"key":"9791_CR11","doi-asserted-by":"publisher","first-page":"e02582-16","DOI":"10.1128\/AAC.02582-16","volume":"61","author":"N Vale","year":"2017","unstructured":"Vale N, Gouveia MJ, Rinaldi G, Brindley PJ, Gartner F, Correia da Costa JM (2017) Praziquantel for schistosomiasis: single-drug metabolism revisited, mode of action, and resistance. Antimicrob Agents Chemother 61:e02582-16","journal-title":"Antimicrob Agents Chemother"},{"key":"9791_CR12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1208\/s12248-016-9885-2","volume":"18","author":"R Shawahna","year":"2016","unstructured":"Shawahna R (2016) Pediatric biopharmaceutical classification system: using age-appropriate initial gastric volume. AAPS J 18:728\u2013736","journal-title":"AAPS J"},{"key":"9791_CR13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0035-9203(90)90333-A","volume":"84","author":"ME Mandour","year":"1990","unstructured":"Mandour ME, el Turabi H, Homeida MM, el Sadig T, Ali HM, Bennett JL, Leahey WJ, Harron DW (1990) Pharmacokinetics of praziquantel in healthy volunteers and patients with schistosomiasis. Trans R Soc Trop Med Hyg 84:389\u2013393","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"9791_CR14","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF03189418","volume":"4","author":"K Patzschke","year":"1979","unstructured":"Patzschke K, Putter J, Wegner LA, Horster FA, Diekmann HW (1979) Serum concentrations and renal excretion in humans after oral administration of praziquantel-results of three determination methods. Eur J Drug Metab Pharmacokinet 4:149\u2013156","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"9791_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10928-018-9601-1","volume":"45","author":"PL Bonate","year":"2018","unstructured":"Bonate PL, Wang T, Passier P, Bagchus W, Burt H, L\u00fcpfert C, Abla N, Kovac J, Keiser J (2018) Extrapolation of praziquantel pharmacokinetics to a pediatric population: a cautionary tale. J Pharmacokinet Pharmacodyn 45:747\u2013762","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9791_CR16","doi-asserted-by":"publisher","first-page":"e00618","DOI":"10.1002\/prp2.618","volume":"8","author":"NN Kapungu","year":"2020","unstructured":"Kapungu NN, Li X, Nhachi C, Masimirembwa C, Thelingwani RS (2020) In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel. Pharmacol Res Perspect 8:e00618","journal-title":"Pharmacol Res Perspect"},{"issue":"Suppl 3","key":"9791_CR17","doi-asserted-by":"publisher","first-page":"A11","DOI":"10.1136\/bmjgh-2019-EDC.26","volume":"4","author":"RS Thelingwani","year":"2019","unstructured":"Thelingwani RS, Kapungu N, Li X, Kanji C, Mutiti C, Reinhard-Rupp WJ, Masimirembwa C (2019) Biotransformation of praziquantel for the pharmacokinetic optimisation of Praziquantel use in mass drug administration and development of new paediatric formulations. BMJ Glob Health 4(Suppl 3):A11\u2013A11. https:\/\/doi.org\/10.1136\/bmjgh-2019-EDC.26","journal-title":"BMJ Glob Health"},{"key":"9791_CR18","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1124\/jpet.106.106013","volume":"318","author":"A Galetin","year":"2006","unstructured":"Galetin A (2006) Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220\u20131229","journal-title":"J Pharmacol Exp Ther"},{"key":"9791_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1124\/dmd.105.008672","volume":"34","author":"MF Paine","year":"2006","unstructured":"Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC (2006) The human intestinal cytochrome P450 \u201cpie\u2019\u2019. Drug Metab Dispos 34:880\u2013886","journal-title":"Drug Metab Dispos"},{"key":"9791_CR20","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00228-019-02663-8","volume":"75","author":"L Nleya","year":"2019","unstructured":"Nleya L, Thelingwani R, Li XQ, Cavallin E, Isin E, Nhachi C, Masimirembwa C (2019) The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel. Eur J Clin Pharmacol 75:1077\u20131087","journal-title":"Eur J Clin Pharmacol"},{"key":"9791_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2710.2007.00862.x","volume":"32","author":"W Ridtitid","year":"2007","unstructured":"Ridtitid W, Ratsamemonthon K, Mahatthanatrakul W, Wongnawa M (2007) Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers. J Clin Pharm Ther 32:585\u2013593","journal-title":"J Clin Pharm Ther"},{"key":"9791_CR22","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1128\/AAC.44.10.2903-2904.2000","volume":"44","author":"N Castro","year":"2000","unstructured":"Castro N, Medina R, Sotelo J, Jung H (2000) Bioavailability of praziquantel increases with concomitant administration of food. Antimicrob Agents Chemother 44:2903\u20132904","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"9791_CR23","doi-asserted-by":"publisher","first-page":"e3265","DOI":"10.1371\/journal.pntd.0003265","volume":"8","author":"R Kasinathan","year":"2014","unstructured":"Kasinathan R, Sharma LK, Cunningham C, Webb T, Greenberg R (2014) Inhibition or knockdown of ABC transporters enhances susceptibility of adult and juvenile schistosomes to praziquantel. PLoS Negl Trop Dis 8(10):e3265","journal-title":"PLoS Negl Trop Dis"},{"key":"9791_CR24","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0001-706X(03)00031-7","volume":"86","author":"AD Dayan","year":"2003","unstructured":"Dayan AD (2003) Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 86:141\u2013159","journal-title":"Acta Trop"},{"issue":"5","key":"9791_CR25","doi-asserted-by":"publisher","first-page":"e0004700","DOI":"10.1371\/journal.pntd.0004700","volume":"10","author":"I Meister","year":"2016","unstructured":"Meister I, Kovac J, Duthaler U, Odermatt P, Huwyler J, Vanobberghen F, Sayasone S, Keiser J (2016) Pharmacokinetic study of praziquantel enantiomers and its main metabolite R-trans-4-OH-PZQ in plasma, blood and dried blood spots in Opisthorchis viverrini-infected patients. PLoS Negl Trop Dis 10(5):e0004700","journal-title":"PLoS Negl Trop Dis"},{"key":"9791_CR26","unstructured":"Bayer (2017) 130920 Biltricide PI. https:\/\/resources.bayer.com.au\/resources\/uploads\/pi\/file9318.pdf"},{"key":"9791_CR27","doi-asserted-by":"publisher","first-page":"e02253-17","DOI":"10.1128\/AAC.02253-17","volume":"62","author":"J Kovac","year":"2018","unstructured":"Kovac J, Meister I, Neodo A, Panic G, Coulibaly JT, Falcoz C, Keiser J (2018) Pharmacokinetics of praziquantel in Schistosoma mansoni- and Schistosoma haematobium-infected school- and preschool-aged children. Antimicrob Agents Chemother 62:e02253-17","journal-title":"Antimicrob Agents Chemother"},{"key":"9791_CR28","doi-asserted-by":"publisher","first-page":"809","DOI":"10.4269\/ajtmh.1994.51.809","volume":"51","author":"MA el Guiniady","year":"1994","unstructured":"el Guiniady MA, el Touny MA, Abdel-Bary MA, Abdel-Fatah SA, Metwally A (1994) Clinical and pharmacokinetic study of praziquantel in Egyptian schistosomiasis patients with and without liver cell failure. Am J Trop Med Hyg 51:809\u2013818","journal-title":"Am J Trop Med Hyg"},{"key":"9791_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1093\/infdis\/157.3.530","volume":"157","author":"G Watt","year":"1988","unstructured":"Watt G, White NJ, Padre L, Ritter W, Fernando MT, Ranoa CP, Laughlin (1988) Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease. J Infect Dis 157:530\u2013535","journal-title":"J Infect Dis"},{"key":"9791_CR30","first-page":"717","volume":"24","author":"K Na Bangchang","year":"1993","unstructured":"Na Bangchang K, Karbwang J, Pungpak S, Radomyos B, Bunnag D (1993) Pharmacokinetics of praziquantel in patients with opisthorchiasis. Southeast Asian J Trop Med Public Health 24:717\u2013723","journal-title":"Southeast Asian J Trop Med Public Health"},{"issue":"9","key":"9791_CR31","doi-asserted-by":"publisher","first-page":"e0008649","DOI":"10.1371\/journal.pntd.0008649","volume":"14","author":"G Zdesenko","year":"2020","unstructured":"Zdesenko G, Mutapi F (2020) Drug metabolism and pharmacokinetics of praziquantel: a review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models. PLoS Negl Trop Dis 14(9):e0008649","journal-title":"PLoS Negl Trop Dis"},{"key":"9791_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.00227-16","volume":"7","author":"AL Bustinduy","year":"2016","unstructured":"Bustinduy AL, Waterhouse D, De Sousa-Figueiredo JC, Roberts SA, Atuhaire A, Van Dam GJ, Corstjens PLAMAMAM, Scott JT, Stanton MC, Kabatereine NB, Ward S, Hope WW, Russell Stothard J (2016) Population pharmacokinetics and pharmacodynamics of praziquantel in Ugandan children with intestinal schistosomiasis: higher dosages are required for maximal efficacy. MBio 7:1\u20139","journal-title":"MBio"},{"key":"9791_CR33","doi-asserted-by":"publisher","first-page":"e00566-20","DOI":"10.1128\/AAC.00566-20","volume":"64","author":"AL Bustinduy","year":"2020","unstructured":"Bustinduy AL, Kolamunnage-Dona R, Mirochnick MH, Capparelli EV, Tallo V, Acosta LP, Olveda RM, Friedman JF, Hope WW (2020) Population pharmacokinetics of praziquantel in pregnant and lactating filipino women infected with schistosoma japonicum. Antimicrob Agents Chemother 64:e00566-20","journal-title":"Antimicrob Agents Chemother"},{"key":"9791_CR34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NHG (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25\u201336","journal-title":"Drug Metab Pharmacokinet"},{"key":"9791_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10928-010-9173-1","volume":"38","author":"M Bouillon-Pichault","year":"2011","unstructured":"Bouillon-Pichault M, Jullien V, Bazzoli C, Pons G, Tod M (2011) Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4. J Pharmacokinet Pharmacodyn 38:25\u201340","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9791_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2165\/00003088-200645090-00005","volume":"45","author":"TN Johnson","year":"2006","unstructured":"Johnson TN, Rostami-Hodjegan A, Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45:931\u2013956","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"9791_CR37","doi-asserted-by":"publisher","first-page":"e38","DOI":"10.1038\/psp.2013.14","volume":"2","author":"DR Mould","year":"2013","unstructured":"Mould DR, Upton RN (2013) Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol 2(4):e38","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9791_CR38","unstructured":"Karlsson MO, Savic R (2006) Overview of absorption models and modelling issues. In: PAGE15, 15th Annu. Meet. Popul. Approach Gr. Eur. 14\u201316 June, 2006, Bruges, Belgium, p (Abstract 1044)"},{"key":"9791_CR39","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1128\/AAC.02318-13","volume":"58","author":"J Tarning","year":"2014","unstructured":"Tarning J, Lindegardh N, Lwin KM, Annerberg A, Kiricharoen L, Ashley E, White NJ, Nosten F, Day NPJJJ (2014) Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria. Antimicrob Agents Chemother 58:2052\u20132058","journal-title":"Antimicrob Agents Chemother"},{"key":"9791_CR40","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-199630050-00001","volume":"30","author":"NHG Holford","year":"1996","unstructured":"Holford NHG (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30:329\u2013332","journal-title":"Clin Pharmacokinet"},{"key":"9791_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.12793\/tcp.2017.25.2.59","volume":"25","author":"N Holford","year":"2017","unstructured":"Holford N (2017) Pharmacokinetic variability due to environmental differences. Transl Clin Pharmacol 25:59\u201362","journal-title":"Transl Clin Pharmacol"},{"key":"9791_CR42","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo YA, Anderson B (2013) A pharmacokinetic standard for babies and adults. J Pharm Sci 102:2941\u20132952","journal-title":"J Pharm Sci"},{"key":"9791_CR43","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJJ Anderson","year":"2008","unstructured":"Anderson BJJ, Holford NHGHG (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"9791_CR44","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/11319350-000000000-00000","volume":"49","author":"MYM Peeters","year":"2010","unstructured":"Peeters MYM, Allegaert K, Bluss Van Oud-Alblas HJ, Cella M, Tibboel D, Danhof M, Knibbe CAJ (2010) Prediction of propofol clearance in children from an allometric model developed in rats, children and adults versus a 0.75 fixed-exponent allometric model. Clin Pharmacokinet 49:269\u2013275","journal-title":"Clin Pharmacokinet"},{"key":"9791_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","volume":"21","author":"BJ Anderson","year":"2011","unstructured":"Anderson BJ, Holford NHG (2011) Tips and traps analyzing pediatric PK data. Paediatr Anaesth 21:222\u2013237","journal-title":"Paediatr Anaesth"},{"key":"9791_CR46","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1128\/AAC.00292-12","volume":"56","author":"TPC Dorlo","year":"2012","unstructured":"Dorlo TPC, Huitema ADR, Beijnen JH, De Vries PJ (2012) Optimal dosing of miltefosine in children and adults with visceral leishmaniasis. Antimicrob Agents Chemother 56:3864\u20133872","journal-title":"Antimicrob Agents Chemother"},{"key":"9791_CR47","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1128\/AAC.02438-12","volume":"57","author":"MA Kamal","year":"2013","unstructured":"Kamal MA, Van Wart SA, Rayner CR, Subramoney V, Reynolds DK, Bulik CC, Smith PF, Bhavnani SM, Ambrose PG, Forrest A (2013) Population pharmacokinetics of oseltamivir: pediatrics through geriatrics. Antimicrob Agents Chemother 57:3470\u20133477","journal-title":"Antimicrob Agents Chemother"},{"key":"9791_CR48","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.1158\/1078-0432.CCR-11-0074","volume":"17","author":"MN Trame","year":"2011","unstructured":"Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G (2011) Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin Cancer Res 17:6867\u20136877","journal-title":"Clin Cancer Res"},{"key":"9791_CR49","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/bcp.12180","volume":"77","author":"C Wang","year":"2014","unstructured":"Wang C, Allegaert K, Peeters MYMMM, Tibboel D, Danhof M, Knibbe CAJJJ (2014) The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol 77:149\u2013159","journal-title":"Br J Clin Pharmacol"},{"key":"9791_CR50","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD (2004) Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6\u201314","journal-title":"Br J Clin Pharmacol"},{"key":"9791_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/03602530902722679","volume":"41","author":"U Klotz","year":"2009","unstructured":"Klotz U (2009) Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67\u201376","journal-title":"Drug Metab Rev"},{"key":"9791_CR52","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U (2011) Age-related changes in pharmacokinetics. Curr Drug Metab 12:601\u2013610","journal-title":"Curr Drug Metab"},{"key":"9791_CR53","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1517\/17425255.2012.698261","volume":"8","author":"MG Mooij","year":"2012","unstructured":"Mooij MG, de Koning BAE, Huijsman ML, de Wildt SN (2012) Ontogeny of oral drug absorption processes in children. Expert Opin Drug Metab Toxicol 8:1293\u20131303","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"9791_CR54","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711\u2013726","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9791_CR55","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10928-012-9247-3","volume":"39","author":"J Shen","year":"2012","unstructured":"Shen J, Boeckmann A, Vick A (2012) Implementation of dose superimposition to introduce multiple doses for a mathematical absorption model (transit compartment model). J Pharmacokinet Pharmacodyn 39:251\u2013262","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9791_CR56","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/pharmaceutics12040330","volume":"12","author":"A Ruiz-Garcia","year":"2020","unstructured":"Ruiz-Garcia A, Tan W, Li J, Haughey M, Masters J, Hibma J, Lin S (2020) Pharmacokinetic models to characterize the absorption phase and the influence of a proton pump inhibitor on the overall exposure of dacomitinib. Pharmaceutics 12(4):330. https:\/\/doi.org\/10.3390\/pharmaceutics12040330","journal-title":"Pharmaceutics"},{"key":"9791_CR57","doi-asserted-by":"publisher","first-page":"66","DOI":"10.12793\/tcp.2015.23.2.66","volume":"2323","author":"J Lee","year":"2015","unstructured":"Lee J, Lim MS, Seong SJ, Park SM, Gwon MR, Han S, Lee SM, Kim W, Yoon YR, Yoo HD (2015) Population pharmacokinetic analysis of the multiple peaks phenomenon in sumatriptan. Transl Clin Pharmacol 2323:66\u201374","journal-title":"Transl Clin Pharmacol"},{"key":"9791_CR58","unstructured":"Krause A, Lavielle M, Chatel K, Kohl C, Kanter RD, Delahaye S, Mackie A, Zisowsky J, Dingemanse J (2013) Modeling the two-peak phenomenon in pharmacokinetics using a gut passage model with two absorption sites. In: PAGE22, 22nd Annu. Meet. Popul. Approach Gr. Eur. Glas. Scotland, 1\u201314 June 2013, p Abstr 2779, ISSN 1871-6032"},{"key":"9791_CR59","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1158\/1078-0432.CCR-13-2846","volume":"20","author":"SC Tate","year":"2014","unstructured":"Tate SC, Cai S, Ajamie RT, Burke T, Beckmann RP, Chan EM, De Dios A, Wishart GN, Gelbert LM, Cronier DM (2014) Semi-mechanistic pharmacokinetic\/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4\/6 inhibitor, in mice bearing human tumor xenografts. Clin Cancer Res 20:3763\u20133774","journal-title":"Clin Cancer Res"},{"key":"9791_CR60","unstructured":"Dunlavey MR, Leary RH (2013) Support in PML for absorption time lag via transit compartments (modeling transit compartments with multiple doses in Phoenix NLME). In: PAGE22, 22nd Annu. Meet. Popul. Approach Gr. Eur. Glas. Scotland, 1\u201314 June 2013, p Abstr 2796"},{"key":"9791_CR61","unstructured":"Dunlavey MHS, Dunlavey M, Hu S (2017) Use of distributed delay in PML. In: PAGE26, 26th Annu. Meet. Popul. Approach Gr. Eur. 6\u20139 June 2017, Budapest, Hungary, p Abstr 6080, ISSN 1871-6032"},{"key":"9791_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10928-018-9570-4","volume":"45","author":"S Hu","year":"2018","unstructured":"Hu S, Dunlavey M, Guzy S, Teuscher N (2018) A distributed delay approach for modeling delayed outcomes in pharmacokinetics and pharmacodynamics studies. J Pharmacokinet Pharmacodyn 45:285\u2013308","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9791_CR63","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jpba.2018.01.030","volume":"151","author":"J Kova\u010d","year":"2018","unstructured":"Kova\u010d J, Panic G, Neodo A, Meister I, Coulibaly JT, Schulz JD, Keiser J (2018) Evaluation of a novel micro-sampling device, $$\\text{ Mitra}^{{\\rm TM}}$$, in comparison to dried blood spots, for analysis of praziquantel in Schistosoma haematobium-infected children in rural C\u00f4te d\u2019Ivoire. J Pharm Biomed Anal 151:339\u2013346","journal-title":"J Pharm Biomed Anal"},{"key":"9791_CR64","unstructured":"R Core Team (2020) A language and environment for statistical computing. https:\/\/www.r-project.org"},{"key":"9791_CR65","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019a) NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacometrics Syst Pharmacol 8:525\u2013537","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9791_CR66","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ (2019b) NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacometrics Syst Pharmacol 8:538\u2013556","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9791_CR67","unstructured":"ICON Clinical Research LLC (2021) NONMEM\u00ae- The gold standard software in Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic modelling. https:\/\/www.iconplc.com\/innovation\/nonmem\/"},{"key":"9791_CR68","unstructured":"Certara (2021) $$\\text{ Phoenix}^{\\rm TM}$$ PK\/PD Platform v 8.3 NEW. Phoenix NLME 8.3, Certara, L.P. 100 Overlook Center, Suite 101, Princeton, NJ, 08540 USA. https:\/\/www.certara.com\/software\/phoenix-pkpd\/"},{"issue":"7","key":"9791_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, Dong J, Ruiz-Garcia A, Sweeney K, Cronenberger C (2013) Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol 2(7):1\u20138","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9791_CR70","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/01.fpc.0000239974.69464.f2","volume":"17","author":"J Sistonen","year":"2007","unstructured":"Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17:93\u2013101","journal-title":"Pharmacogenet Genomics"},{"key":"9791_CR71","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/FPC.0b013e32831ebb30","volume":"19","author":"J Sistonen","year":"2009","unstructured":"Sistonen J, Fuselli S, Palo JU, Chauhan N, Padh H, Sajantila A (2009) Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 19:170\u2013179","journal-title":"Pharmacogenet Genomics"},{"key":"9791_CR72","unstructured":"Data W (2019) Average height and weight by country. https:\/\/www.worlddata.info\/average-bodyheight.php"},{"key":"9791_CR73","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/j.1365-2125.2008.03289.x","volume":"66","author":"JF Standing","year":"2008","unstructured":"Standing JF, Howard RF, Johnson A, Savage I, Wong ICKKK (2008) Population pharmacokinetics of oral diclofenac for acute pain in children. Br J Clin Pharmacol 66:846\u2013853","journal-title":"Br J Clin Pharmacol"},{"key":"9791_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-016-1134-8","volume":"15","author":"S Birgersson","year":"2016","unstructured":"Birgersson S, Van Toi P, Truong NT, Dung NT, Ashton M, Hien TT, Abel\u00f6 A, Tarning J (2016) Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. Malar J 15:1\u201310","journal-title":"Malar J"},{"key":"9791_CR75","doi-asserted-by":"publisher","first-page":"e02401","DOI":"10.1128\/AAC.02401-16","volume":"61","author":"AM Hopkins","year":"2017","unstructured":"Hopkins AM, Wojciechowski J, Abuhelwa AY, Mudge S, Upton RN, Foster DJR (2017) Population pharmacokinetic model of doxycycline plasma concentrations using pooled study data. Antimicrob Agents Chemother 61:e02401-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"9791_CR76","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1038\/psp.2013.59","volume":"2","author":"F Kloprogge","year":"2013","unstructured":"Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, Lindeg\u00e5rdh N, Nosten F, Day NPJJJ, White NJ, Guerin PJ, Tarning J (2013) Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated plasmodium falciparum malaria in Uganda. CPT Pharmacometrics Syst Pharmacol 2(11):e83","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"9791_CR77","first-page":"5695","volume":"60","author":"F Vanobberghen","year":"2016","unstructured":"Vanobberghen F, Penny MA, Duthaler U, Odermatt P, Sayasone S, Keiser J (2016) Population pharmacokinetic modeling of tribendimidine metabolites in Opisthorchis viverrini\u2014infected adults. Am Soc Microbiol 60:5695\u20135704","journal-title":"Am Soc Microbiol"}],"updated-by":[{"DOI":"10.1007\/s10928-022-09807-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000}}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-021-09791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-021-09791-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-021-09791-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T14:21:26Z","timestamp":1652365286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-021-09791-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["9791"],"URL":"https:\/\/doi.org\/10.1007\/s10928-021-09791-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10928-022-09807-x","asserted-by":"object"}]},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,13]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10928-022-09807-x","URL":"https:\/\/doi.org\/10.1007\/s10928-022-09807-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}